Pharmaceutical Commerce - June 2018 - 22

F E AT U R E

manual or spreadsheet-based.
Where business has been
With this Big Data challenge, effective compliance with track
c o n d u c t e d d i g i t a l l y, t h e
and trace regulations will be difficult to achieve through existing
files exchanged have been
infrastructure and approaches. The pharmaceutical industry is no
transactional in nature and
different than any others in that it has built up silos of information
have not allowed for anything
to be tracked. There has been
in its ERP, MES and warehouse management systems.
no way to analyze that supply
chain data to address any of
exchange between supply chain partners. In an industry
the counterfeiting, diversion or supply chain performance
that jealously guards its data for competitive advantage,
issues that companies are faced with.
the track and trace solution needs to find a way to make the
The track and trace legislation forces every company to
right data available in a way that can be accessed in a secure
address this situation. The first step is to realize that you are
way that doesn't add risk to intellectual property.
not just handling the product, you're handling the product
The answer is likely to be a track and trace solution that's
data. To move any product along the supply chain means
based around an enterprise data management platform that
accommodating a complex set of requirements on how data
can contain all the relevant data and enable secure access
is created, managed, stored and accessed as the product
across the supply chain - and for regulators if required.
passes from manufacturer to patient - and you have to be
The platform can deliver the end-to-end visibility
able to do this at scale.
required. In fact, OpenText operates the world's largest
There's often a range of unintended consequences that
business network with over $7 trillion dollars of business
fall out of government regulation. In this case, it's the sheer
transacted each year. It enables the automated processing of
volume of data that a track and trace solution creates in
key business documents and transactions between trading
the supply chain. It's highly unlikely that those regulators
partners. [4]
that created the legislation had a clear understanding of the
The interesting point is that, often, companies on
huge data sets, transaction volumes or network interaction
our business network use it to analyze elements of their
required for effective track and trace compliance.
business as the network is the place where they can gain the
Nor could they foresee the way that technologies advance
visibility into their transaction. It's a good example of how a
to meet business requirements. For example, chemical
global data management platform facilitates the use of AI to
taggants are being used to protect both the product and
deploy the predictive analytics necessary to achieve supply
the packaging. Smart labels are appearing that enable much
chain improvements.
more information to be added above the identifiers - such
as prescribing guidance or adverse side effects.
AI: Driving the business benefits of track and trace
The result of which is that the track and trace solution
While it's difficult to find research into the specific
must be able to accommodate not just the volume of data
benefits that an effective track and trace solution can
but also the variety - both structured data, such as label
bring, a McKinsey report from 2012 [5] estimated that a
information, and unstructured data, such as adverse side
pharmaceutical manufacturer with 25 packaging lines and
effects.
$4 billion in revenues could see the following benefits from
With this Big Data challenge, effective compliance
track and trace:
with track and trace regulations will be difficult to achieve
through existing infrastructure and approaches. The
* $90 million from inventory cuts
pharmaceutical industry is no different than any others in
* $11 million/year from reduced inventory financing
that it has built up silos of information in its ERP, MES and
and holding
warehouse management systems. Customization of these
* $4 million/year reduced waste
systems is unlikely to work and will prove challenging to
* $3-12 million/year from reduced recalls
maintain as regulatory requirements change of over time.
* $25-35 million/year from reduced loss to counterfeiting
In addition, the levels of supply chain visibility required
for track and trace need high levels of collaboration and data

22 \ Visit our website at www.PharmaceuticalCommerce.com \ 06.2018


http://www.PharmaceuticalCommerce.com

Table of Contents for the Digital Edition of Pharmaceutical Commerce - June 2018

Table of Contents
Pharmaceutical Commerce - June 2018 - Cover1
Pharmaceutical Commerce - June 2018 - Cover2
Pharmaceutical Commerce - June 2018 - Table of Contents
Pharmaceutical Commerce - June 2018 - 4
Pharmaceutical Commerce - June 2018 - 5
Pharmaceutical Commerce - June 2018 - 6
Pharmaceutical Commerce - June 2018 - 7
Pharmaceutical Commerce - June 2018 - 8
Pharmaceutical Commerce - June 2018 - 9
Pharmaceutical Commerce - June 2018 - 10
Pharmaceutical Commerce - June 2018 - 11
Pharmaceutical Commerce - June 2018 - 12
Pharmaceutical Commerce - June 2018 - 13
Pharmaceutical Commerce - June 2018 - 14
Pharmaceutical Commerce - June 2018 - 15
Pharmaceutical Commerce - June 2018 - 16
Pharmaceutical Commerce - June 2018 - 17
Pharmaceutical Commerce - June 2018 - 18
Pharmaceutical Commerce - June 2018 - 19
Pharmaceutical Commerce - June 2018 - 20
Pharmaceutical Commerce - June 2018 - 21
Pharmaceutical Commerce - June 2018 - 22
Pharmaceutical Commerce - June 2018 - 23
Pharmaceutical Commerce - June 2018 - 24
Pharmaceutical Commerce - June 2018 - 25
Pharmaceutical Commerce - June 2018 - 26
Pharmaceutical Commerce - June 2018 - 27
Pharmaceutical Commerce - June 2018 - 28
Pharmaceutical Commerce - June 2018 - 29
Pharmaceutical Commerce - June 2018 - 30
Pharmaceutical Commerce - June 2018 - 31
Pharmaceutical Commerce - June 2018 - 32
Pharmaceutical Commerce - June 2018 - 33
Pharmaceutical Commerce - June 2018 - 34
Pharmaceutical Commerce - June 2018 - Cover3
Pharmaceutical Commerce - June 2018 - Cover4
http://www.nxtbook.com/nxtbooks/pharmcomm/201909
http://www.nxtbook.com/nxtbooks/pharmcomm/201906
http://www.nxtbook.com/nxtbooks/pharmcomm/201903
http://www.nxtbook.com/nxtbooks/pharmcomm/201811
http://www.nxtbook.com/nxtbooks/pharmcomm/201809
http://www.nxtbook.com/nxtbooks/pharmcomm/201806
http://www.nxtbook.com/nxtbooks/pharmcomm/20180304
http://www.nxtbook.com/nxtbooks/pharmcomm/20171112
http://www.nxtbook.com/nxtbooks/pharmcomm/20170910
http://www.nxtbook.com/nxtbooks/pharmcomm/20170708
http://www.nxtbook.com/nxtbooks/pharmcomm/20170506
http://www.nxtbook.com/nxtbooks/pharmcomm/20170304
http://www.nxtbook.com/nxtbooks/pharmcomm/20170102
http://www.nxtbook.com/nxtbooks/pharmcomm/20161112
http://www.nxtbook.com/nxtbooks/pharmcomm/20160910
http://www.nxtbook.com/nxtbooks/pharmcomm/20160708
http://www.nxtbook.com/nxtbooks/pharmcomm/20160506
http://www.nxtbook.com/nxtbooks/pharmcomm/20160304
http://www.nxtbook.com/nxtbooks/pharmcomm/20160102
http://www.nxtbook.com/nxtbooks/pharmcomm/20151112
http://www.nxtbook.com/nxtbooks/pharmcomm/20150910
http://www.nxtbook.com/nxtbooks/pharmcomm/20150708
http://www.nxtbook.com/nxtbooks/pharmcomm/20150506
http://www.nxtbook.com/nxtbooks/pharmcomm/20150304
http://www.nxtbook.com/nxtbooks/pharmcomm/20150102
http://www.nxtbook.com/nxtbooks/pharmcomm/20141112
http://www.nxtbook.com/nxtbooks/pharmcomm/coldchaindirectory2014
http://www.nxtbook.com/nxtbooks/pharmcomm/20140910
http://www.nxtbook.com/nxtbooks/pharmcomm/20140708
http://www.nxtbook.com/nxtbooks/pharmcomm/20140506
http://www.nxtbook.com/nxtbooks/pharmcomm/20140304
http://www.nxtbook.com/nxtbooks/pharmcomm/20140102
http://www.nxtbook.com/nxtbooks/pharmcomm/dataservicedirectory
http://www.nxtbook.com/nxtbooks/pharmcomm/20131112
http://www.nxtbook.com/nxtbooks/pharmcomm/20130910_hubreport
http://www.nxtbook.com/nxtbooks/pharmcomm/20130910
http://www.nxtbook.com/nxtbooks/pharmcomm/20130708
http://www.nxtbook.com/nxtbooks/pharmcomm/20130506
http://www.nxtbook.com/nxtbooks/pharmcomm/coldchain2013
http://www.nxtbook.com/nxtbooks/pharmcomm/20130304
http://www.nxtbook.com/nxtbooks/pharmcomm/20130102
http://www.nxtbook.com/nxtbooks/pharmcomm/20121112
http://www.nxtbook.com/nxtbooks/pharmcomm/20120910
http://www.nxtbook.com/nxtbooks/pharmcomm/20120708
http://www.nxtbook.com/nxtbooks/pharmcomm/20120506
http://www.nxtbook.com/nxtbooks/pharmcomm/20120506_coldchain
http://www.nxtbook.com/nxtbooks/pharmcomm/20120304
http://www.nxtbook.com/nxtbooks/pharmcomm/20120102
http://www.nxtbook.com/nxtbooks/pharmcomm/20111112
http://www.nxtbook.com/nxtbooks/pharmcomm/20110910
http://www.nxtbook.com/nxtbooks/pharmcomm/20110708
http://www.nxtbook.com/nxtbooks/pharmcomm/20110506
http://www.nxtbook.com/nxtbooks/pharmcomm/20110304
http://www.nxtbook.com/nxtbooks/pharmcomm/20110102
http://www.nxtbook.com/nxtbooks/pharmcomm/20101112
http://www.nxtbook.com/nxtbooks/pharmcomm/20100910
http://www.nxtbook.com/nxtbooks/pharmcomm/20100708
http://www.nxtbook.com/nxtbooks/pharmcomm/20100506
http://www.nxtbook.com/nxtbooks/pharmcomm/201004
http://www.nxtbook.com/nxtbooks/pharmcomm/201003
http://www.nxtbook.com/nxtbooks/pharmcomm/20100102
http://www.nxtbook.com/nxtbooks/pharmcomm/20091112
http://www.nxtbookMEDIA.com